News >

Considerations for CAR T-Cell Therapy in NHL

Angelica Welch
Published: Friday, Jan 19, 2018

Babis Andreadis, MD

Babis Andreadis, MD
Chimeric antigen receptor (CAR) T-cell therapy exploded onto the scene in 2017 with the approval of tisagenlecleucel (Kymriah) in acute lymphoblastic leukemia (ALL) and axicabtagene ciloleucel (axi-cel; Yescarta) in non-Hodgkin lymphoma (NHL).

State of the Science SummitTM on Hematologic Malignancies, Babis Andreadis, MD, associate professor of clinical medicine, Department of Medicine, director, Clinical Research Support Office, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, reflected on the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.

OncLive: Please provide an overview of your presentation on CAR T-cell therapy in NHL.

Andreadis: We are living in an exciting era in lymphoma therapy because of the recent developments in immunotherapy, specially CAR T-cell therapies. In 2017, we saw the approval of 2 novel therapies in patients with ALL and diffuse large B-cell lymphoma. My talk focused on how these therapies work and what are the expected management complications and toxicities associated with them. In the lymphoma sphere, we know that both therapies can produce 30% to 40% long-term responders, meaning people who are out 6 months or more with a complete response. The goal is to determine whether those patients can be seen as longer-term responders and eventually be cured. We think CAR T-cell therapy has the ability to do that.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication